Standout Papers

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced ... 2019 2026 2021 2023 255
  1. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial (2019)
    Yi‐Long Wu, Shun Lü et al. Journal of Thoracic Oncology

Immediate Impact

4 from Science/Nature 59 standout
Sub-graph 1 of 24

Citing Papers

Artificial intelligence in drug development
2025 Standout
Lactate and lactylation in cancer
2025 Standout
2 intermediate papers

Works of Hai-Yan Tu being referenced

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
2019 Standout

Author Peers

Author Last Decade Papers Cites
Hai-Yan Tu 182 235 18 33 5 260
Pascale Dubray Longeras 211 262 13 44 3 289
Joanna Wójcik-Tomaszewska 128 219 14 53 3 245
Grygorii Ursol 131 209 10 50 6 238
Mayank Gandhi 234 284 19 41 9 310
Farah Louise Lim 146 225 10 52 7 257
Joanne Riemer 130 220 19 40 9 254
S. Chaléat 185 293 18 53 2 322
M. Grangeon 185 293 18 53 2 322
Yuriy Ostapenko 128 113 63 19 6 188
Seigo Sasaki 149 283 36 45 6 316

All Works

Loading papers...

Rankless by CCL
2026